Highlights and Prescribing Information on Tivicay, © 2013, revised August 2013 (“Tivicay Label”) Shah et al., “Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV,” 34(5) PHARMACOTHERAPY 506– 20 (2014) (“Shah”)
US Patent Publication 2016/0016973 (US ’973) Tsiang et al., “Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile,” 60(12) ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 7086–97 (2016) (“Tsaing”)
EVALUATION AND RESEARCH (CDER), “Guidance for Industry: Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules,” (June 2015) (“CDER Guidance”) Sabin et al., “Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration,” 371 LANCET 1417–26 (2008) (“Sabin”) Press Release, Gilead, “Gilead Announces Phase 3 Result for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)” (November 5, 2015) (“Gilead November 2015 Press Release”) Stellbrink et al., “Dolutegravir in Antiretroviral-naive Adults with HIV-1: 96-week Results from a Randomized Dose-ranging Study,” 27 AIDS 1771–78 (2013) (“Stellbrink”) Highlights and Prescribing Information on Epzicom, © 2004 (“Epzicom Label”) Benjamin E. Blass, “Drug Discovery and Development: An Overview of Modern Methods and Principles” in BASIC PRINCIPLES OF DRUG DISCOVERY AND DEVELOPMENT 1–34 (Elsevier Sci. & Tech., 2015), published April 27, 2015 (“Blass Chapter 1”) Benjamin E. Blass, “Medicinal Chemistry” in BASIC PRINCIPLES OF DRUG DISCOVERY AND DEVELOPMENT 203–43 (Elsevier Sci. & Tech., 2015), published April 27, 2015 (“Blass Chapter 5”) Chen et al., “Prediction of Absolute Hydroxyl pKa Values for 3‑Hydroxypyridin-4-ones,” 3 J.
Michael R. Franklin & Donald N. Franz, “Chapter 57: Drug Absorption, Action, and Disposition,” in 21 REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1142–70 (Lippincott Williams & Wilkins ed., 2006) (“Remington Chapter 57”) Paul M. Beringer & Michael E. Winter, “Chapter 59: Clinical Pharmacokinetics and Pharmacodynamics,” in 21 REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1191–1205 (Lippincott Williams & Wilkins ed., 2006) (“Remington Chapter 59”) Raymond E. Galinsky & Craig K. Svensson, “Chapter 58: Basic Pharmacokinetics and Pharmacodynamics,” in 21 REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 1171–90 (Lippincott Williams & Wilkins ed., 2006) (“Remington Chapter 58”) “Chapter 17: Ionic Solutions and Electrolytic Equilibria,” in 21
Description Howard Y. Ando & Galen W. Radebaugh, “Chapter 38: Property- Based Drug Design and Preformulation,” in 21 REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 720–44 (Lippincott Williams and Wilkins ed., 2006) (“Remington Chapter 38”) Zolopa et al., “Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial,” 201 J.